| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-treated fibroblasts by blocking plasminogen activator inhibitor-1 expression and activating plasminogen
1 Department of Environmental Health Sciences, University of Alabama at Birmingham, Birmingham, AL, USA
* To whom correspondence should be addressed. E-mail: rliu{at}uab.edu.
Transforming growth factor-beta (TGF-
) plays an important role in tissue fibrogenesis. We previously demonstrated that GSH supplementation blocked collagen accumulation induced by TGF- in NIH3T3 cells. In the present study, we show that supplementation of reduced glutathione (GSH) restores the collagen degradation rate in TGF- treated NIH3T3 cells. Restoration of collagen degradation by GSH is associated with a reduction of type I plasminogen activator inhibitor (PAI-1) expression/activity as well as recovery of the activities of cell-associated tissue-type plasminogen activator (t-PA) and plasmin. Furthermore, we find that NIH-3T3 cells constitutively express plasminogen mRNA and possess plasmin activity. Blockade of cell surface binding of plasminogen/plasminogen activation with tranexamic acid (TXA) or inhibition of plasmin activity with aprotinin significantly reduces the basal level of collagen degradation both in the presence or absence of exogenous plasminogen. Most importantly, addition of TXA or active PAI-1 almost completely eliminates the restorative effects of GSH on collagen degradation in TGF- treated cells. Taken together, our results suggest that the major mechanism by which GSH restores collagen degradation in TGF--treated cells is through blocking PAI-1 expression, leading to an increased PA/plasmin activity and consequent proteolytic degradation of collagens. This study provides mechanistic evidence for GSH's putative therapeutic effect in the treatment of fibrotic disorders.
This article has been cited by other articles:
|
|
 |
|
  E. Kuramoto, T. Nishiuma, K. Kobayashi, M. Yamamoto, Y. Kono, Y. Funada, Y. Kotani, T. H. Sisson, R. H. Simon, and Y. Nishimura Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model Am J Physiol Lung Cell Mol Physiol, March 1, 2009; 296(3): L337 - L346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Vayalil, K. E. Iles, J. Choi, A.-K. Yi, E. M. Postlethwait, and R.-M. Liu Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1281 - L1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kariya, H. Leitner, E. Min, C. van Heeckeren, A. van Heeckeren, and B. J. Day A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1590 - L1597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Matsuoka, T. H. Sisson, T. Nishiuma, and R. H. Simon Plasminogen-Mediated Activation and Release of Hepatocyte Growth Factor from Extracellular Matrix Am. J. Respir. Cell Mol. Biol., December 1, 2006; 35(6): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
